Earlier this morning, Arena Pharmaceuticals announced that the Phase 3 trial results for their new obesity drug Lorcaserin met all efficacy and safety endpoints.

And yet, in just 2 1/2  hours of trading, their share price had dropped by over 32%.

But….they met all their efficacy and safety endpoints.

Why would the market punish a company for meeting all of their efficacy and safety endpoints?

I just don’t get it.

Based on Arena’s data, the average Lorcaserin patient:

  • started out at 219 lbs,
  • lost 12.7 lbs, and
  • ended up at 201.3 lbs.

In contrast, the placebo patient:

  • started out at 213.6 lb,
  • lost 4.7 lbs, and
  • ended up at 208.9 lbs

That means that over the course of 12 months, the Lorcaserin patient lost 8 more pounds than the patient taking the placebo.

8 lbs.

8 lbs over 12 months?

That’s it?

One of my new personal training clients is down 14 pounds in just under 7 weeks.

Another has lost just under 30 pounds since the new year.

Another has lost over 200 pounds over the past few years.


So, why would anyone want to take Lorcaserin?

For the side effects?


To be fair, Health Habits isn’t without side effects:

  • Lowered blood pressure
  • Lowered resting heart rate
  • Lowered appetite for sweets
  • Increased strength, endurance, flexibility, confidence, and
  • Inappropriate comments in the workplace


If you like what you see here, click here for updates


Related Posts